Childhood medulloblastoma

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 1, 2011, Pages 65-83

  Massimino, Maura ^a   Giangaspero, Felice ^b   Garrè, Maria Luisa ^c   Gandola, Lorenza ^a   Poggi, Geraldina ^d   Biassoni, Veronica ^a   Gatta, Gemma ^a   Rutkowski, Stefan ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Late effects; Medulloblastoma; Pediatric brain tumors; Prognosis; Rehabilitation in brain tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; VINCRISTINE;

ADJUVANT THERAPY; AGE DISTRIBUTION; BONE DISEASE; BRAIN RADIATION; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CHILDHOOD CANCER; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DYSLIPIDEMIA; FOLLOW UP; GONADAL DISEASE; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; MEDULLOBLASTOMA; METABOLIC SYNDROME X; METASTASIS; MINIMAL RESIDUAL DISEASE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUROPATHOLOGY; OBESITY; ONSET AGE; OSTEOPENIA; OSTEOPOROSIS; PROGNOSIS; RADIATION DOSE; REVIEW; RISK FACTOR; SECOND CANCER; SENSORY DYSFUNCTION; SEX DIFFERENCE; THYROID NODULE; TREATMENT INDICATION;

CEREBELLAR NEOPLASMS; CHILD; FOLLOW-UP STUDIES; HUMANS; MEDULLOBLASTOMA; TREATMENT OUTCOME;

EID: 79957933718     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.010     Document Type: Review

References (112)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Peris-Bonet R., Martinez-Garcia C., Lacour B., et al. Childhood central nervous system tumours-incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2064-2080.
3. Gatta G., Zigon G., Capocaccia R., et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45:992-1005.
4. Harder T., Plagemann A., Harder A. Birth weight and subsequent risk of childhood primary brain tumors: a meta-analysis. Am J Epidemiol 2008, 168:366-373.
5. Fear N.T., Roman E., Ansell P., Bull D. Malignant neoplasms of the brain during childhood: the role of prenatal and neonatal factors (United Kingdom). Cancer Causes Control 2001, 12:443-449.
6. Harding N.J., Birch J.M., Hepworth S.J., McKinney P.A. Infectious exposure in the first year of life and risk of central nervous system tumors in children: analysis of day care, social contact, and overcrowding. Cancer Causes Control 2009, 20:129-136.
7. Pogoda J.M., Preston-Martin S., Howe G., et al. An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol 2009, 19:148-160.
8. Bunin G.R., Kuijten R.R., Buckley J.D., Rorke L.B., Meadows A.T. Relation between maternal diet and subsequent primitive neuroectodermal brain tumors in young children. N Engl J Med 1993, 329:536-541.
9. Thorne R.N., Pearson A.D., Nicoll J.A., et al. Decline in incidence of medulloblastoma in children. Cancer 1994, 74:3240-3244.
10. Baldwin R.T., Preston-Martin S. Epidemiology of brain tumors in childhood-a review. Toxicol Appl Pharmacol 2004, 199:118-131.
11. UKCCSI.UK Childhood Cancer Study Investigators Exposure to power-frequency magnetic fields and the risk of childhood cancer. Lancet 1999, 354:1925-1931.
12. Li P., McLaughlin J., Infante-Rivard C. Maternal occupational exposure to extremely low frequency magnetic fields and the risk of brain cancer in the offspring. Cancer Causes Control 2009, 20:945-955.
13. Shim Y.K., Mlynarek S.P., van W.E. Parental exposure to pesticides and childhood brain cancer: U.S. Atlantic coast childhood brain cancer study. Environ Health Perspect 2009, 117:1002-1006.
14. Rosso A.L., Hovinga M.E., Rorke-Adams L.B., Spector L.G., Bunin G.R. A case-control study of childhood brain tumors and fathers' hobbies: a Children's Oncology Group study. Cancer Causes Control 2008, 19:1201-1207.
15. Cordier S., Lefeuvre B., Filippini G., et al. Parental occupation, occupational exposure to solvents and polycyclic aromatic hydrocarbons and risk of childhood brain tumors (Italy, France, Spain). Cancer Causes Control 1997, 8:688-697.
16. Giangaspero F., Eberhart C.G., Ellison D.W., et al. Medulloblastoma. WHO classification of tumours of the nervous system 2007, IARC, Lyon. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavanee (Eds.).
17. Gilbertson R.J., Ellison D.W. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008, 3:341-365.
18. McManamy C.S., Pears J., Weston C.L., et al. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 2007, 17:151-164.
19. Garre M.L., Cama A., Bagnasco F., et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin Cancer Res 2009, 15:2463-2471.
20. Eberhart C.G., Kepner J.L., Goldthwaite P.T., et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002, 94:552-560.
21. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352:978-986.
22. McManamy C.S., Lamont J.M., Taylor R.E., et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 2003, 62:627-632.
23. Lo K.C., Rossi M.R., Eberhart C.G., Cowell J.K. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol 2007, 17:282-296.
24. Ellison D.W., Onilude O.E., Lindsey J.C., et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005, 23:7951-7957.
25. Rutkowski S., von B.A., von H.K., et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007, 13:2651-2657.
26. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24:1924-1931.
27. Kool M., Koster J., Bunt J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3:e3088.
28. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005, 11:17-22.
29. Fan X., Eberhart C.G. Medulloblastoma stem cells. J Clin Oncol 2008, 26:2821-2827.
30. Buhring U., Strayle-Batra M., Freudenstein D., Scheel-Walter H.G., Kuker W. MRI features of primary, secondary and metastatic medulloblastoma. Eur Radiol 2002, 12:1342-1348.
31. Gajjar A., Fouladi M., Walter A.W., et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999, 17:1825-1828.
32. Packer R.J., Rood B.R., MacDonald T.J. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003, 39:60-67.
33. Chang C.H., Housepian E.M., Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969, 93:1351-1359.
34. Grotzer M.A., Hogarty M.D., Janss A.J., et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001, 7:2425-2433.
35. Evans A.E., Jenkin R.D., Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990, 72:572-582.
36. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7:813-820.
37. Gandola L., Massimino M., Cefalo G., et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009, 27:566-571.
38. Duffner P.K., Horowitz M.E., Krischer J.P., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993, 328:1725-1731.
39. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005, 6:573-580.
40. Albright A.L., Sposto R., Holmes E., et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000, 47:879-885.
41. Robertson P.L., Muraszko K.M., Holmes E.J., et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 2006, 105:444-451.
42. Packer R.J., Sutton L.N., Elterman R., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994, 81:690-698.
43. Brand W.N., Schneider P.A., Tokars R.P. Long-term results of a pilot study of low dose cranial-spinal irradiation for cerebellar medulloblastoma. Int J Radiat Oncol Biol Phys 1987, 13(11):1641-1645.
44. Goldwein J.W., Radcliffe J., Johnson J., et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996, 34:899-904.
45. Halberg F.E., Wara W.M., Fippin L.F., et al. Low-dose craniospinal radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 1991, 20:651-654.
46. Tomita T., McLone D.G. Medulloblastoma in childhood: results of radical resection and low-dose neuraxis radiation therapy. J Neurosurg 1986, 64:238-242.
47. Packer R.J. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990, 28:823-828.
48. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24:4202-4208.
49. Thomas P.R., Deutsch M., Kepner J.L., et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000, 18:3004-3011.
50. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.
51. Carrie C., Muracciole X., Gomez F., et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 2005, 63:711-716.
52. Tait D.M., Thornton-Jones H., Bloom H.J., Lemerle J., Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990, 26:464-469.
53. Packer R.J., Siegel K.R., Sutton L.N., et al. Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: a preliminary report. Ann Neurol 1988, 24:503-508.
54. Bailey C.C., Gnekow A., Wellek S., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995, 25:166-178.
55. Gentet J.C., Bouffet E., Doz F., et al. Preirradiation chemotherapy including " eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 1995, 82:608-614.
56. Verlooy J., Mosseri V., Bracard S., et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 2006, 42:3004-3014.
57. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999, 17:832-845.
58. Kortmann R.D., Kuhl J., Timmermann B., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT'91. Int J Radiat Oncol Biol Phys 2000, 46:269-279.
59. Strother D., Ashley D., Kellie S.J., et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001, 19:2696-2704.
60. Dhodapkar K., Dunkel I.J., Gardner S., et al. Preliminary results of dose intensive pre-irradiation chemotherapy in patients older than 10 years of age with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Med Pediatr Oncol 2002, 38:47-48.
61. Chi S.N., Gardner S.L., Levy A.S., et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004, 22:4881-4887.
62. Taylor R.E., Bailey C.C., Robinson K.J., et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 2005, 41:727-734.
63. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995 1999, National Cancer Institute, SEER Program, Bethesda, MD, NHI (Pub No. 99-4649). L. Ries, M. Smith, J.G. Gurney (Eds.).
64. Milchaski A., Garre M.L. Infants brain tumours. Brain and spinal tumours of childhood 2004, 359-369. Arnold Publishers, London, UK. D.A. Walker, G. Perilongo, J. Punt, R.E. Taylor (Eds.).
65. Garrè M.L., Massimino M., Cefalo G., et al. High-risk malignant CNS tumours in infants: standard vs mieloablative chemotherapy: the experience of the Italian cooperative study for children <3 years of age. Neuro-oncol 2003, 1:40.
66. Ater J.L., van E.J., Woo S.Y., et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol 1997, 32:243-252.
67. Duffner P. Pediatric neurology 2003, Lippincott Williams & Wilkins.
68. Duffner P.K., Horowitz M.E., Krischer J.P., et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-Oncol 1999, 1:152-161.
69. Rutkowski S., Gerber N.U., von H.K., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncol 2009, 11:201-210.
70. Geyer J.R., Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005, 23:7621-7631.
71. Dallorso S., Dini G., Ladenstein R., et al. Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours. Bone Marrow Transplant 2005, 35(Suppl. 1):S31-S34.
72. Kalifa C., Valteau D., Pizer B., et al. High-dose chemotherapy in childhood brain tumours. Childs Nerv Syst 1999, 15:498-505.
73. Amlashi S.F., Riffaud L., Brassier G., Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003, 98:618-624.
74. Heikens J., Michiels E.M., Behrendt H., et al. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 1998, 34:1592-1597.
75. Darzy K.H., Shalet S.M. Hypopituitarism following radiotherapy revisited. Endocr Dev 2009, 15:1-24. [Epub: 2009 March 3:1-24].
76. Fossati P., Ricardi U., Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 2009, 35:79-96.
77. Ogilvy-Stuart A.L., Shalet S.M. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995, 73:141-146.
78. Bull K.S., Spoudeas H.A., Yadegarfar G., Kennedy C.R. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol 2007, 25:4239-4245.
79. Rose S.R. Endocrinopathies in childhood cancer survivors. Endocrinologist 2003, 13:488-495.
80. Sklar C.A., Mertens A.C., Mitby P., et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002, 87:3136-3141.
81. GHS.Growth Hormone (GH) Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 2000, 85:3990-3993.
82. Rutter M.M., Rose S.R. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007, 19:480-487.
83. Nandagopal R., Laverdiere C., Mulrooney D., Hudson M.M., Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008, 69:65-74.
84. Anderson N.E. Late complications in childhood central nervous system tumour survivors. Curr Opin Neurol 2003, 16:677-683.
85. Corrias A., Einaudi S., Ricardi U., et al. Thyroid diseases in patients treated during pre-puberty for medulloblastoma with different radiotherapic protocols. J Endocrinol Invest 2001, 24:387-392.
86. Toogood A.A. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004, 14(Suppl. A):S118-S124.
87. Krishnamoorthy P., Freeman C., Bernstein M.L., Lawrence S., Rodd C. Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors. Arch Pediatr Adolesc Med 2004, 158:491-496.
88. Palmer S.L., Reddick W.E., Gajjar A. Understanding the cognitive impact on children who are treated for medulloblastoma. J Pediatr Psychol 2007, 32:1040-1049.
89. Palmer S.L. Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed conceptual model. Dev Disabil Res Rev 2008, 14:203-210.
90. Mabbott D.J., Penkman L., Witol A., Strother D., Bouffet E. Core neurocognitive functions in children treated for posterior fossa tumors. Neuropsychology 2008, 22:159-168.
91. Mulhern R.K., Palmer S.L., Reddick W.E., et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001, 19:472-479.
92. Reeves C.B., Palmer S.L., Reddick W.E., et al. Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 2006, 31:272-280.
93. Hardy K.K., Bonner M.J., Willard V.W., Watral M.A., Gururangan S. Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma. Psychooncology 2008, 17:1157-1161.
94. Mulhern R.K., Kepner J.L., Thomas P.R., et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998, 16:1723-1728.
95. Jain N., Krull K.R., Brouwers P., Chintagumpala M.M., Woo S.Y. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer 2008, 51:275-279.
96. Mulhern R.K., Palmer S.L., Merchant T.E., et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005, 23:5511-5519.
97. Askins M.A., Moore B.D. Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol 2008, 23:1160-1171.
98. Packer R.J., Gurney J.G., Punyko J.A., et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003, 21:3255-3261.
99. Odame I., Duckworth J., Talsma D., et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer 2006, 46:357-362.
100. Hartley K.A., Li C., Laningham F.H., Krasin M.J., Xiong X., Merchant T.E. Vertebral body growth after craniospinal irradiation. Int J Radiat Oncol Biol Phys 2008, 70:1343-1349.
101. Goldstein A.M., Yuen J., Tucker M.A. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 1997, 8:865-871.
102. Minn A.Y., Pollock B.H., Garzarella L., et al. Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. J Clin Oncol 2001, 19:4135-4140.
103. Ridola V., Grill J., Doz F., et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007, 110:156-163.
104. Bouffet E., Doz F., Demaille M.C., et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?. Br J Cancer 1998, 77:1321-1326.
105. Massimino M., Gandola L., Spreafico F., et al. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys 2009, 73:1358-1363.
106. Saran F., Baumert B.G., Creak A.L., et al. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer 2008, 50:554-560.
107. Kadota R.P., Stewart C.F., Horn M., et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors-a pediatric oncology group phase II study. J Neurooncol 1999, 43:43-47.
108. Hurwitz C.A., Strauss L.C., Kepner J., et al. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol 2001, 23:277-281.
109. Dreyer Z.E., Kadota R.P., Stewart C.F., et al. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro-oncol 2003, 5:261-267.
110. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007, 110:1542-1550.
111. Bomgaars L.R., Bernstein M., Krailo M., et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol 2007, 25:4622-4627.
112. Kieran M.W., Turner C.D., Rubin J.B., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005, 27:573-581.